Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biofeedback vs Botox for Dyssynergic Defecation
NCT06724250Phase 4Completed
- Sponsor
- Mansoura University
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of botulinum toxin type A in obstructed defecation syndrome (ODS) (2 arms), sponsored by Mansoura University. Primary endpoint: Improvement of symptoms of constipation at 1 year. Started Aug 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
obstructed defecation syndrome (ODS)
Beyond the preview
Go deeper on NCT06724250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724250.